Top
Topic: SBRT and Immunotherapy for the Management of HCC: a recent Appraisal

A special issue of Hepatoma Research

ISSN 2454-2520 (Online), ISSN 2394-5079 (Print)

Submission deadline: 30 Dec 2019

Guest Editor(s)

  • Jia Fan, MD
    Department of Liver Surgery, Zhongshan Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Fudan University, Shanghai 200032, P.R. China.
    Department of Molecular Cell Biology, Institute of Biomedical Sciences, Fudan University, Shanghai 200032, P.R. China.

    E-mail

Special Issue Introduction

Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer, leading to more than 700 thousand deaths annually. In recent years, immunotherapy has emerged as a novel, effective systemic treatment for advanced HCC and potentially suppress tumor recurrence and metastasis. However, the objective response rate of simply immunologic agent treatment for HCC is still unsatisfactory. The combination of conventional treatments including stereotactic body radiation therapy (SBRT) with specific immunotherapeutic approaches may dramatically improve outcome of HCC patients. Moreover, the advancement of SBRT techniques has allowed for a safer administration of higher levels of dose to liver cancer while minimizing the potential liver toxicities. In this edition of Hepatoma Research, we will discuss new advances in SBRT, immunotherapy, and combined strategies for the treatment of patients with liver cancer.

Participants

Lewis R. Roberts  Mayo Clinic, Rochester, United States
Chen Dong  Tsinghua University, Beijing, China
Chen Liu  Rutgers New Jersey Medical School, Newark, United States
Antonio Bertoletti  Duke-NUS Medical School Singapore, Singapore City, Singapore
Peter Suenaert&Alex Karlsson-Parra  Immunicum AB, Stockholm, Sweden
Aparna Jayachandran&Ritu Shrestha  Greenslopes Private Hospital, Brisbane, Australia (under processing)
Liliana Montella  "S.Maria delle Grazie" Hospital Pozzuoli (Naples)- ASL Naples 2 Nord, Italy
Chun-Hong Ma  Shandong University, Jinan, China
Smruti R. Mohanty  New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, USA
Ming Chen&Ning Zhou  Zhejiang Cancer Hospital, Hangzhou, China
Chunfeng Qu  National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Tan To Cheung  The University of Hong Kong, Queen Mary Hospital, Hong Kong, China
Hong Yao  XuZhou Medical University, Xuzhou, China
Dong-Ming Kuang  Sun Yat-Sen University Cancer Center, Guangzhou, China
Yong Zeng  West China Hospital of Sichuan University, Chengdu, China
Yee-Min Jen  Triservice General Hospital Taiwan, Taipei, Taiwan
Yu-Min Li  Key Laboratory of Digestive System Tumors of Gansu, Lanzhou, China
Xun-Di Xu  Second Xiangya Hospital of Central-South University, Changsha, China
Shu-Qun Cheng&Xiu-Ping Zhang  The National Research Cooperative Group for Diagnosis and Treatment of Hepatocellular Carcinoma with Tumour Thrombus, Shanghai, China
Xue-Fu Wang  Anhui Medical University, Hefei, China
Li Wang  Infectious Disease Hospital of Yantai, Shandong, China
The list is arranged in no particular order and being updated.

Submission Deadline

30 Dec 2019

Submission Information

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to http://hrjournal.net/pages/view/author_instructions
For Online Submission, please login at http://www.oaemesas.com/hr
Submission Deadline: 30 Dec 2019
Contacts: Haidi Ding, Assistant Editor, editor001@hrjournal.net

Published Articles

This special issue is now open for submission.